# KEYNOTE-866 (NCT03924856)

> Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03924856
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Bladder Cancer
- Interventions: Pembrolizumab; Gemcitabine; Cisplatin; Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]); Placebo
- Enrollment: 907
- Primary outcome: Event-Free Survival (EFS)

## Commentary we found

- YouTube: 10
- X threads: 6
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-866-nct03924856

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03924856", "email": "<work email>"}; the inbox owner confirms by the emailed link.